CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Moolky Nagabhushan, Casey M. Miller, Theresa P. Pretlow, Joseph M. Giaconia, Nancy L. Edgehouse, Stuart Schwartz, Hsing Jien Kung, Ralph W. De Vere White, Paul H. Gumerlock, Martin I. Resnick, Saeid B. Amini, Thomas G. Pretlow

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

Original languageEnglish
Pages (from-to)3042-3046
Number of pages5
JournalCancer Research
Volume56
Issue number13
Publication statusPublished - Jul 1 1996
Externally publishedYes

Fingerprint

Heterografts
Androgens
Agar
Prostatic Neoplasms
Prostate-Specific Antigen
Recurrence
Neoplasms
Castration
Transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., ... Pretlow, T. G. (1996). CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research, 56(13), 3042-3046.

CWR22 : The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar. / Nagabhushan, Moolky; Miller, Casey M.; Pretlow, Theresa P.; Giaconia, Joseph M.; Edgehouse, Nancy L.; Schwartz, Stuart; Kung, Hsing Jien; De Vere White, Ralph W.; Gumerlock, Paul H.; Resnick, Martin I.; Amini, Saeid B.; Pretlow, Thomas G.

In: Cancer Research, Vol. 56, No. 13, 01.07.1996, p. 3042-3046.

Research output: Contribution to journalArticle

Nagabhushan, M, Miller, CM, Pretlow, TP, Giaconia, JM, Edgehouse, NL, Schwartz, S, Kung, HJ, De Vere White, RW, Gumerlock, PH, Resnick, MI, Amini, SB & Pretlow, TG 1996, 'CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar', Cancer Research, vol. 56, no. 13, pp. 3042-3046.
Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S et al. CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research. 1996 Jul 1;56(13):3042-3046.
Nagabhushan, Moolky ; Miller, Casey M. ; Pretlow, Theresa P. ; Giaconia, Joseph M. ; Edgehouse, Nancy L. ; Schwartz, Stuart ; Kung, Hsing Jien ; De Vere White, Ralph W. ; Gumerlock, Paul H. ; Resnick, Martin I. ; Amini, Saeid B. ; Pretlow, Thomas G. / CWR22 : The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar. In: Cancer Research. 1996 ; Vol. 56, No. 13. pp. 3042-3046.
@article{222a8a09b8144e2db5d075ccc1857df6,
title = "CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar",
abstract = "Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.",
author = "Moolky Nagabhushan and Miller, {Casey M.} and Pretlow, {Theresa P.} and Giaconia, {Joseph M.} and Edgehouse, {Nancy L.} and Stuart Schwartz and Kung, {Hsing Jien} and {De Vere White}, {Ralph W.} and Gumerlock, {Paul H.} and Resnick, {Martin I.} and Amini, {Saeid B.} and Pretlow, {Thomas G.}",
year = "1996",
month = "7",
day = "1",
language = "English",
volume = "56",
pages = "3042--3046",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - CWR22

T2 - The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

AU - Nagabhushan, Moolky

AU - Miller, Casey M.

AU - Pretlow, Theresa P.

AU - Giaconia, Joseph M.

AU - Edgehouse, Nancy L.

AU - Schwartz, Stuart

AU - Kung, Hsing Jien

AU - De Vere White, Ralph W.

AU - Gumerlock, Paul H.

AU - Resnick, Martin I.

AU - Amini, Saeid B.

AU - Pretlow, Thomas G.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

AB - Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

UR - http://www.scopus.com/inward/record.url?scp=0029942883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029942883&partnerID=8YFLogxK

M3 - Article

C2 - 8674060

AN - SCOPUS:0029942883

VL - 56

SP - 3042

EP - 3046

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -